An observational study in Hematological Neoplasm and Endothelial Dysfunction, sponsored by Prof. Dr. Thomas Luft. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-08.
Sponsored by Prof. Dr. Thomas Luft · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 65 studies in Hematologic Neoplasms with a site in Germany — 20 open to participants now, 28 under way, 3 of them phase 3. Hematologic Neoplasms · Germany.
Among the 65 studies in Hematologic Neoplasms with a site in Germany, this one is the 5th largest by planned enrollment of the 15 observational ones that give a count, is one of 4 that started in 2022, is one of 15 observational ones, reaches primary completion later than 10 of the 27 other live ones, and was the 51st registered.
1,449 studies on the registry are indexed under Hematologic Neoplasms; 422 are open to participants now.
Browse Hematologic Neoplasms studies →20 of the 65 studies in Hematologic Neoplasms with a site in Germany are open now. Recruiting first, the newest first:
Technical University of Munich · Sites in Germany
CSL Behring · Sites in Germany, United States, Belgium and 8 more countries
Ages 18+
Technical University of Munich · Sites in Germany
Ages 18+
Kura Oncology, Inc. · Sites in Germany, United States, Australia and 14 more countries
Ages 18+
Swedish Orphan Biovitrum · Sites in Germany, United States, Canada and 5 more countries
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 313 Hematologic Neoplasms studies recruiting now, 209 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
65 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 25 · Phase 3 13
First in 1995; this study’s year is marked. 4 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,000 is above the median of 191 across 324 observational studies indexed under Hematologic Neoplasms.
Median enrollment 91 across the 50 interventional studies, 450 across the 15 observational. Of the 32 that completed or were terminated, 14 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
47 of 65 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Prof. Dr. Thomas Luft as lead sponsor.
Prof. Dr. Thomas Luft has 1 study filed under Hematologic Neoplasms — fewer than ten, so there is no comparison to draw.
9 of the studies in Hematologic Neoplasms with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07519811Technical University of MunichLLM-Generated Plain-Language Patient Synopses to Improve Comprehension in Hematology and Oncology (oncOPAL) | 2026-12-31 |
| NCT03735992Universität Duisburg-EssenMind-body Medicine for Patients With Malignant Hematological Diseases | 2026-12-31 |
| NCT07939139Technical University of MunichShadow-Mode Evaluation of an AI Assistant for Multidisciplinary Tumor Boards | 2027-01-31 |
| NCT06645886Kumquat Biosciences Inc.A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic Malignancies | 2027-03 |
| NCT05502887Prof. Dr. Thomas LuftThe Endothelial Cell Dysfunction and Outcome Project for Hematological Neoplasms | 2027-06-07 |
Add all 9 to your calendar (.ics) → With an account.
Among the 65 studies in Hematologic Neoplasms with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The endothelium is a semipermeable monolayer of endothelial cells (EC) organized as a complex biological interface that separates all tissues from circulating blood. Any anti-neoplastic or immune therapy will directly challenge the endothelial layer, with a substantial risk of damaging EC or exacerbating pre-existing endothelial cell dysfunction.
In our previous researchs the concepts of "endothelial vulnerability" and "endothelial cell dysfunction" for initial diagnosis of patients with hematological disorders, e.g. myelodysplastic syndromes as well as COVID-19 patients were designed. The novel and pre-existing endothelial vulnerability markers and markers of endothelial cell dysfunction or damage such as endothelial activation and stress index (EASIX) were also defined, validated and their prognostic role for treatment-related mortality and for a variety of allo- and CART-specific endothelial complications were established. However, the exact relationship of EASIX and other markers with endothelial cell biology are not known and require further clarification.
Primary aims are to demonstrate that EASIX represents a systemic response of the organism to local or systemic loss of endothelial glycocalyx as visualized by sublingual microscopy and to establish EASIX, biomarkers and in vivo microscopy of sublingual and (in perspective) recto-sigmoidal capillary beds as prognostic markers of response to anti-neoplastic therapy, treatment-related toxicity and mortality (TRM) and overall survival (OS). Secondary objectives include the creation of a comprehensive database with information on endothelial, clinical, pathological and molecular characteristics of patients with hematological malignancies as well as the establishment of a repository of biospecimens for endothelial marker analyses from patients with hematological malignancies.
We hypothesize that reduced endothelial glycocalyx thickness will permit direct interactions of leukocytes and platelets with endothelial cells, resulting in cellular activation (increased LDH), loss of platelets due to activation and microembolism, and ensuing kidney damage. As a first prospective analysis, we will answer the question if EASIX and serum endothelial biomarkers correlate with sublingual glycocalyx thickness, and if these parameters combine to predict outcome after anti-neoplastic therapy including alloSCT and CART.
Functional heterogeneity is a hallmark of the endothelial cell system. The hypothetical functional definition of ECs as input-output devices emphasizes their role as direct responders to a variety of challenges such as blood pressure, temperature, pH and oxygen pressure, and serum factors. Maintaining homeostasis of tissue perfusion is an important function of ECs that are continuously exposed to stimuli provided by the alternative complement pathway, coagulation factors, cytokines, activated platelets, leukocytes, and occasional infectious agents. Due to their distribution over space and time, hardly two ECs will be exposed to the same set of input signals 8. Moreover, stochastic or inheritable heterogeneous DNA methylation patterns add to the functional variability of seemingly "homogeneous" mature EC populations. Therefore, tissue-specific stress responses of ECs can explain that even during systemic EC dysfunction (e.g. due to calcineurin inhibitors, viruses, TBI etc.), microangiopathy develops locally in individual patients. This functional heterogeneity has to be considered in all attempts to define clinical diagnostic criteria for endothelial complications after hematological anti-neoplastic therapy including alloSCT and CART infusions.
Over the last years, our group has developed the concepts of "endothelial vulnerability" and "endothelial cell dysfunction" that pre-exist before alloSCT and CART infusions and at initial diagnosis of patients with hematological disorders, e.g. myelodysplastic syndromes, but also in COVID-19 patients. We have defined and validated novel and pre-existing endothelial vulnerability markers (e.g. single nucleotide polymorphisms in THBD (Thrombomodulin) and CD40 Ligand; serum levels of Angiopoietin-2, serum nitrates, asymmetric dimethyl-arginine (ADMA), testosterone deficiency, interleukin-18), and markers of endothelial cell dysfunction or damage (e.g. suppressor of tumorigenicity (ST)-2, interleukin-18, insulin-like growth factor 1 (IGF1), CXCL8), and we have established their role as prognostic markers for treatment-related mortality and for a variety of allo- and CART-specific endothelial complications.
The heterogeneity of EC explains why global one-for-all markers were not found within the group of endothelial-derived and endothelial-specific prognostic factors. We therefore developed the Endothelial activation and stress index, EASIX, as a marker that represents the response of the organism to endothelial dysfunction. EASIX represents an interplay of the basic laboratory parameters (LDH*creatinine/platelets) observed at onset of the most severe endothelial complication after alloSCT, i.e. transplant-associated thrombotic microangiopathy (TAM). EASIX correlated with endothelial serum markers such as IL18, ANG2 and IGF1 and predicted outcome in a variety of clinical settings including COVID-19. However, the exact relationship of EASIX to endothelial cell biology requires further clarification. We hypothesize that reduced endothelial glycocalyx thickness will permit direct interactions of leukocytes and platelets with endothelial cells, resulting in cellular activation (increased LDH), loss of platelets due to activation and microembolism, and ensuing kidney damage.
Thus, key areas of interest are:
The above challenges are ideally met by a registry study with a sufficient population size to answer relevant questions in rare therapy-related complications and rare cancer entities.
The aim is to set up a registry study that covers systematic and comprehensive clinical data acquisition, and longitudinal banking of serum, blood cells and bone marrow samples of patients with hematological diseases, with focus on in vivo microscopy, EASIX, and serum endothelial markers.
This resource will spur patient-oriented investigations into relationships between endothelial, clinical and tumor-biological parameters in hematological neoplasms and lay the groundwork for novel, supportive treatment approaches protecting the endothelial system in poorly understood and difficult-to-treat subsets.
As a first prospective analysis, we will answer the question if EASIX and serum endothelial biomarkers correlate with sublingual glycocalyx thickness, and if these parameters combine to predict outcome after anti-neoplastic therapy including alloSCT and CART.
All patients with newly diagnosed or preexistent hematological neoplasms at participating centers are intended to be registered within EndoCDO-H. Prior to inclusion, patients have to give their written informed consent.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All patients with newly diagnosed or preexistent hematological neoplasms at participating centers are intended to be registered within EndoCDO-H. Prior to inclusion, patients have to give their written informed consent.
Diagnostic Test: Sublingual in vivo microscopy with the Glycocheck microscope
For the collection of longitudinal microscopy data, sublingual in vivo microscopy with the Glycocheck microscope will be performed at the following timepoints: 2-3 x between day (D) -28 of allogeneic HSCT or CAR T cell therapy and before start of the conditioning regimen, once between D2-D14, once between D15-28, once between D30- D100 and at the onset of endothelial complications such as acute GvHD, TMA, sepsis, VOD and IPS following allogeneic HSCT or CAR T cell therapy. Sublingual microscopy requires 15-30 minutes and is similar to sublingual temperature measurement. To this extent, a tube with a diameter of approximately 1cm carrying a microscope at the tip is inserted into the mouth and under the tongue to measure endothelial structures (blood flow through small capillaries). Biological samples are collected and processed within the established Biobank of the Internal Medicine V of the Heidelberg University Hospital.
overall survival
Time period between date of informed consent to alive at last follow-up or death
Time frame: observation peroid 10 years
side effects
toxicity measured according to CTC AE version 5.0
Time frame: observation peroid 10 years
Treatment adaptation
reduction of dose intensity
Time frame: observation peroid 10 years
endothelial glycocalyx
endothelial glycocalyx measured by sublingual microscopy
Time frame: observation peroid 10 years
Plan to share: No
Started Sep 2022 (actual). Primary completion is estimated for Jun 2027, 57 months after the start.
Of 164 non-industry observational studies under Hematologic Neoplasms, half reached primary completion within 74 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 322. This study's planned 57 months is below that.
Counting every sponsor, half of 186 studies reached it within 74 months; a quarter within 34 and three quarters within 322.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.